Free Trial
NASDAQ:RXRX

Recursion Pharmaceuticals (RXRX) Stock Price, News & Analysis

Recursion Pharmaceuticals logo
$4.89 +0.06 (+1.24%)
Closing price 04:00 PM Eastern
Extended Trading
$4.88 0.00 (-0.10%)
As of 05:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Recursion Pharmaceuticals Stock (NASDAQ:RXRX)

Key Stats

Today's Range
$4.82
$4.94
50-Day Range
$4.77
$6.54
52-Week Range
$3.79
$12.36
Volume
11.41 million shs
Average Volume
24.58 million shs
Market Capitalization
$2.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Consensus Rating
Hold

Company Overview

Recursion Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

RXRX MarketRank™: 

Recursion Pharmaceuticals scored higher than 45% of companies evaluated by MarketBeat, and ranked 672nd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Recursion Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Recursion Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Recursion Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Recursion Pharmaceuticals are expected to grow in the coming year, from ($1.57) to ($1.42) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Recursion Pharmaceuticals is -2.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Recursion Pharmaceuticals is -2.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Recursion Pharmaceuticals has a P/B Ratio of 2.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Recursion Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    35.39% of the float of Recursion Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Recursion Pharmaceuticals has a short interest ratio ("days to cover") of 4.2.
  • Change versus previous month

    Short interest in Recursion Pharmaceuticals has recently increased by 1.74%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Recursion Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Recursion Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    35.39% of the float of Recursion Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Recursion Pharmaceuticals has a short interest ratio ("days to cover") of 4.2.
  • Change versus previous month

    Short interest in Recursion Pharmaceuticals has recently increased by 1.74%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Recursion Pharmaceuticals has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.97 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Recursion Pharmaceuticals this week, compared to 10 articles on an average week.
  • Search Interest

    81 people have searched for RXRX on MarketBeat in the last 30 days. This is an increase of 1% compared to the previous 30 days.
  • MarketBeat Follows

    47 people have added Recursion Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 42% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Recursion Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $202,026.00 in company stock.

  • Percentage Held by Insiders

    Only 8.43% of the stock of Recursion Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    89.06% of the stock of Recursion Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Recursion Pharmaceuticals' insider trading history.
Receive RXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Recursion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RXRX Stock News Headlines

Recursion to Participate in Upcoming Investor Conferences
Take a look at this picture ...
A strange investment secret — discovered just a few short weeks before this image was taken — correctly predicted it all. Even crazier, this secret accurately called every major financial event in recent history … Now it's signaling something very scary is about to hit the market again …tc pixel
Needham Maintains Buy Rating on Recursion (RXRX)
See More Headlines

RXRX Stock Analysis - Frequently Asked Questions

Recursion Pharmaceuticals' stock was trading at $6.76 at the start of the year. Since then, RXRX stock has decreased by 27.6% and is now trading at $4.8950.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) issued its quarterly earnings data on Tuesday, August, 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.06. The firm's revenue for the quarter was up 33.3% on a year-over-year basis.
Read the conference call transcript
.

Recursion Pharmaceuticals (RXRX) raised $306 million in an initial public offering on Friday, April 16th 2021. The company issued 18,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink, Allen & Co. and KeyBanc Capital Markets acted as the underwriters for the IPO.

Top institutional shareholders of Recursion Pharmaceuticals include ARK Investment Management LLC (8.12%), Sumitomo Mitsui Trust Group Inc. (2.01%), Nikko Asset Management Americas Inc. (2.01%) and Geode Capital Management LLC (1.91%). Insiders that own company stock include Mubadala Investment Co Pjsc, Blake Borgeson, Michael Secora, Christopher Gibson, Najat Khan, Tina Marriott, Dean Y Li, Tina Marriott Larson, Shafique Virani, Terry-Ann Burrell and Zavain Dar.
View institutional ownership trends
.

Shares of RXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Recursion Pharmaceuticals investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
8/05/2025
Today
8/27/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RXRX
CIK
1601830
Employees
400
Year Founded
N/A

Price Target and Rating

High Price Target
$10.00
Low Price Target
$5.00
Potential Upside/Downside
+43.0%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.78)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$463.66 million
Net Margins
-1,004.91%
Pretax Margin
-1,004.88%
Return on Equity
-76.09%
Return on Assets
-54.29%

Debt

Debt-to-Equity Ratio
0.02
Current Ratio
3.58
Quick Ratio
3.58

Sales & Book Value

Annual Sales
$58.84 million
Price / Sales
36.12
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.12 per share
Price / Book
2.31

Miscellaneous

Outstanding Shares
434,150,000
Free Float
397,553,000
Market Cap
$2.13 billion
Optionable
Optionable
Beta
0.93
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:RXRX) was last updated on 8/27/2025 by MarketBeat.com Staff
From Our Partners